Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.
Chronic myeloid leukaemia
generic imatinib
treatment-free remission
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
medline:
13
4
2023
entrez:
11
4
2023
pubmed:
12
4
2023
Statut:
ppublish
Résumé
Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasibility and efficacy of TFR in patients on generic Imatinib. In this single-centre prospective Generic Imatinib-Free Trial-in-CML-CP study, twenty six patients on generic imatinib for ≥3 yr and in sustained deep molecular response (BCR ABL At a median follow up of 33 months (interquartile range 18.7-35), 42.3 per cent patients (n=11) continued to be in TFR. Estimated TFR at one year was 44 per cent. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of molecularly undetectable leukaemia (>MR The study adds to the growing literature that generic imatinib is effective and can be safely discontinued in CML-CP patients who are in deep molecular remission.
Sections du résumé
Background & objectives
Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasibility and efficacy of TFR in patients on generic Imatinib.
Methods
In this single-centre prospective Generic Imatinib-Free Trial-in-CML-CP study, twenty six patients on generic imatinib for ≥3 yr and in sustained deep molecular response (BCR ABL
Results
At a median follow up of 33 months (interquartile range 18.7-35), 42.3 per cent patients (n=11) continued to be in TFR. Estimated TFR at one year was 44 per cent. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of molecularly undetectable leukaemia (>MR
Interpretation & conclusions
The study adds to the growing literature that generic imatinib is effective and can be safely discontinued in CML-CP patients who are in deep molecular remission.
Identifiants
pubmed: 37040232
pii: IndianJMedRes_2023_157_1_87_370611
doi: 10.4103/ijmr.ijmr_1090_21
pmc: PMC10284370
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Drugs, Generic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-91Références
Haematologica. 2016 Jun;101(6):717-23
pubmed: 26888022
Ann Hematol. 2015 Apr;94 Suppl 2:S249-57
pubmed: 25814091
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Haematologica. 2019 Jul;104(7):e293-e295
pubmed: 30630987
Leuk Lymphoma. 2014 Dec;55(12):2813-6
pubmed: 24724785
Cancer Med. 2019 Nov;8(15):6559-6565
pubmed: 31502383
Ann Hematol. 2012 Aug;91(8):1245-50
pubmed: 22526369
J Oncol Pract. 2017 Jun;13(6):352-355
pubmed: 28445102
Am Health Drug Benefits. 2019 Nov;12(7):333-342
pubmed: 32055281
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
J Oncol Pharm Pract. 2015 Feb;21(1):76-9
pubmed: 24561549
Leuk Lymphoma. 2014 Dec;55(12):2678-80
pubmed: 24798742
J Glob Oncol. 2018 Sep;4:1-10
pubmed: 30241224
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e526-e531
pubmed: 31239209
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Leuk Lymphoma. 2014 Dec;55(12):2830-4
pubmed: 24628295
Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):457-462
pubmed: 28559151
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Indian J Hematol Blood Transfus. 2019 Jan;35(1):1-2
pubmed: 30828139
Blood. 2013 May 30;121(22):4439-42
pubmed: 23620577
Haematologica. 2019 Jul;104(7):e330
pubmed: 31257208